NSTE-ACS患者PCI术后应用替格瑞洛双抗血小板治疗的2年追踪分析

doi:10.3969/j.issn.1671-7171.2018.04.016

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the long-term effect of tigrilol dual antiplatelet therapy after percutaneous coronary stenting (PCI) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACSC).【Methods】The clinical data of 500 patients diagnosed by coronary angiography and treated with PCI from May 2013 to January 2016 were retrospectively analyzed. The patients were divided into two groups: the observation group (n=256) and the control group (n=244). The patients in the observation group were treated with tigrello double antiplatelet therapy, and the control group were treated with routine double antiplatelet therapy. The biochemical indexes and left ventricular ejection fraction (LVEF) were observed and compared before and after treatment in the two groups. Adverse reactions and major adverse cardiovascular events within 2 years (MACEE) and bleeding events.【Results】After treatment, the levels of serum creatinine and LVEF in the two groups were significantly higher than those in the control group. The indexes of Cr and LVEF in the observation group was significantly higher than those in the control group (P<0.05). The serum creatine kinase isoenzyme (CK-MB), troponin I (cTnI) and platelet maximum aggregation rate (MPAR) in the two groups were significantly lower than those before treatment, and the decrease in the observation group was significantly higher than that in the control group (P<0.05). After 12 and 24 months follow-up, the incidence of total MACE and total haemorrhage events in the observation group was significantly lower than that in the control group, After 12 and 24 months follow-up, the incidence of total MACE and total haemorrhage events in the observation group was significantly lower than that in the control group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 11.33% (29/256) and in the control group was 14.75% (36/244).There was no significant difference in the incidence of adverse reactions between the two groups (χ²=1.296, P>0.05).【Conclusion】Tigrilol has a good inhibitory effect on platelet aggregation after PCI in patients with NSTE-ACS, and has a rapid effect. Stable drug effect does not increase the adverse reactions of patients. It can reduce the incidence of long-term MACE and is worthy of clinical application.

Key words： Acute Coronary Syndrome/TH Angioplasty, Transluminal, Percutaneous Coronary Platelet Aggregation Inhibitors/TU

Received: 06 April 2017

PACS:

R543.31

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2018.04.016 OR http://www.jcr.net.cn/EN/Y2018/V35/I4/672

[1] 杨丽霞,郭瑞威.《中国经皮冠状动脉介入治疗指南(2016)》指导急性冠状动脉综合征的临床实践[J].中国介入心脏病学杂志,2016,24(12):714-717.
[2] 郭一洁,邹晓,司全金.抗血小板药物研究进展[J].中华老年多器官疾病杂志,2017,16(9):699-702.
[3] 黄莉,王选琦,吴晓鹏.急性冠状动脉综合征合并糖尿病患者经皮冠状动脉介入术后替格瑞洛与氯吡格雷抗血小板疗效及预后研究[J].中华老年多器官疾病杂志,2017,16(11):846-849.
[4] 詹晓燕,林玉蓓,胡杰,等.血栓弹力图监测冠心病患者PCI术后替格瑞洛和氯吡格雷抗血小板治疗效果研究[J].中国循证心血管医学杂志,2017,9(9):1108-1111.
[5] 王正东,李平,林智海,等.血管损伤及PCI术后再狭窄机制的研究进展和相应对策[J].医学综述,2016,22(2):280-283.
[6] 李晓利,范利,张金花,等.血栓弹力图花生四烯酸诱导血小板聚集率与临床及实验室指标的相关性分析[J].中华老年心脑血管病杂志,2016,18(10):1030-1033.
[7] 邹俊,李欣,邓明凤,等.氯吡格雷血小板反应多样性研究进展[J].药物不良反应杂志,2016,18(1):46-51.
[8] 李相冬,王志远,孟繁波,等.ABCB1及CYP2C19基因多态性对氯吡格雷治疗的影响[J].中国循证心血管医学杂志,2017,9(2):243-245.
[9] 顾颖,李攀,杨雅薇,等.替格瑞洛在急性冠脉综合征治疗中的应用进展[J].国际心血管病杂志,2016,43(4):200-203.
[10] 杨影红,孙鑫,田野.替格瑞洛增强腺苷生物学效应的研究进展[J].临床心血管病杂志,2015,13(2):122-124.
[11] 李旭东,路雯,李明哲,等.氯吡格雷弱代谢患者改服替格瑞洛的安全性及临床疗效观察[J].中国动脉硬化杂志,2015,23(11):1163-1166.
[12] 贾国伟.急性冠脉综合征PCI术后患者应用替格瑞洛及氯吡格雷治疗的临床效果比较[J].中国医药导刊,2016,18(2):181-182.
[13] 刘杰,吕孝欣,孟春,等.替格瑞洛和双倍剂量氯吡格雷治疗氯吡格雷抵抗急性冠脉综合征的疗效及安全性[J].山东医药,2017,57(1):61-63.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(5): 958-959.